The U.S. Food and Drug Administration (FDA) recently granted King Pharmaceuticals approval to market Duodote(tm) (atropine and pralidoxime chloride injection) as a treatment for chemical nerve agent poisoning to EMS personnel. Duodote(tm) is a single, dual-chambered auto-injector containing two separate drug products, atropine and pralidoxime chloride.
Duodote(tm) is intended for administration in the event of chemical nerve agent and insecticide poisoning. The auto-injector is a pre-filled, ready-to-use unit designed to treat symptoms caused by chemical nerve agents, and organophosphorous insecticides. Duodote(tm) replaces the Mark I(tm) Nerve Agent Auto-Injector Kit that currently is used by the U.S. Department of DeAfense and allied nations, as well as EMS personnel in the U.S. The Mark I(tm) contains two separate auto-injectors (two separate injections) - one containing atropine and one containing pralidoxime chloride.